{
  "ticker": "BOT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967026",
  "id": "02967026",
  "pages": 24,
  "price_sensitive": false,
  "date": "20250708",
  "time": "0830",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250708/pdf/06lkxdtxhvn166.pdf",
  "summary": "**Key Material Information from Botanix Pharmaceuticals Sofdra\u2122 Launch Update (8 July 2025):**  \n\n- **Commercial Performance:**  \n  - **Gross Sales:** ~$25M AUD (January\u2013June 2025), with steady monthly growth (June: $8.3M AUD).  \n  - **Prescriptions:** Over 16,000 TRx filled since February 2025 launch; June TRx reached 5,570.  \n  - **Prescriber Base:** 2,300+ unique prescribers in June (up from 75 in January).  \n  - **Refill Rates:** Exceed industry average (3.4 fills/patient vs. 2 fills/year benchmark).  \n\n- **Gross-to-Net (GTN) Metrics:**  \n  - GTN yield improved to **23%** by June (from 13% at launch), tracking toward **30\u201340% target**.  \n  - Fully reimbursed claims rose **50%** since launch; high-deductible claims fell **75%**.  \n\n- **Strategic Initiatives:**  \n  - **Sales Force Expansion:** Field team expanded from **27 to 50 reps** (Q3 2025\u2013Q2 2026).  \n  - **Medical Engagement:** Phase 3 data published in *Journal of American Academy of Dermatology* (July 2025).  \n\n- **Benchmark Comparison:**  \n  - Sofdra\u2019s early launch metrics (e.g., TRx/rep, net revenue/rep) exceed Arcutis\u2019 ZORYVE\u00ae performance.  \n\n**Omitted:** Non-material operational details, forward-looking estimates, legal disclaimers, and repetitive data visuals.",
  "usage": {
    "prompt_tokens": 5519,
    "completion_tokens": 350,
    "total_tokens": 5869,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-07T22:48:04.647188"
}